公开(公告)号：US20210163465A1

公开(公告)日：2021-06-03

申请号：US17123265

申请日：2020-12-16

Applicant: Bristol-Myers Squibb Company

Inventor： Xiaojun Zhang ,  Eldon Scott Priestley ,  J. Alex Bates ,  Oz Scott Halpern ,  Samuel Kaye Reznik ,  Jeremy M. Richter

IPC: C07D417/04 ,  A61P7/04 ,  A61P9/10 ,  C07D405/04 ,  C07D405/14 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D513/04 ,  C07D519/00 ,  C07D403/04

Abstract: Disclosed are compounds of Formula (I) to (VIII): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a bicyclic heteroaryl group substituted with zero to 3 R3a; and R1, R2, R3a, R4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.

公开(公告)号：US20190023701A1

公开(公告)日：2019-01-24

申请号：US15756367

申请日：2016-08-30

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Joanne M. Smallheer ,  Scott A. Shaw ,  Oz Scott Halpern ,  Carol Hui Hu ,  Ellen K. Kick

IPC: C07D471/04

CPC classification number: C07D471/04 ,  C07D487/08

Abstract: The present invention provides compounds of Formula (I): wherein A is as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments.

公开(公告)号：US20240309019A1

公开(公告)日：2024-09-19

申请号：US18530405

申请日：2023-12-06

Applicant: Bristol-Myers Squibb Company

Inventor： Xiaojun Zhang ,  Eldon Scott Priestley ,  Oz Scott Halpern ,  Wen Jiang ,  Samuel Kaye Reznik ,  Jeremy M. Richter

IPC: C07D519/00 ,  A61P7/02 ,  C07D515/14

CPC classification number: C07D519/00 ,  A61P7/02 ,  C07D515/14

Abstract: Disclosed are compounds of Formula (I) to (VIII):




or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a tricyclic heteroaryl group substituted with R3a and zero to 2 R3b; and R1, R2, R3a, R3b, R4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.

公开(公告)号：US20210188877A1

公开(公告)日：2021-06-24

申请号：US17142288

申请日：2021-01-06

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Xiaojun Zhang ,  Eldon Scott Priestley ,  Oz Scott Halpern ,  Wen Jiang ,  Samuel Kaye Reznik ,  Jeremy M. Richter

IPC: C07D519/00 ,  A61P7/02 ,  C07D515/14

Abstract: Disclosed are compounds of Formula (I) to (VIII): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a tricyclic heteroaryl group substituted with R3a and zero to 2 R3b; and R1, R2, R3a, R3b, R4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.

公开(公告)号：US20200291015A1

公开(公告)日：2020-09-17

申请号：US16083951

申请日：2017-03-10

Applicant: Bristol-Myers Squibb Company

Inventor： Joanne M. Smallheer ,  Carol Hui HU ,  Meriah Neissel Valente ,  Scott A. Shaw ,  Benjamin P. Vokits ,  Oz Scott Halpern

IPC: C07D471/04

Abstract: The present invention provides compounds of Formula (I). wherein A and Z are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and may be useful for the treatment and/or prophylaxis of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.

公开(公告)号：US10577383B2

公开(公告)日：2020-03-03

申请号：US16099010

申请日：2017-06-26

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Joanne M. Smallheer ,  Ellen K. Kick ,  Meriah Neissel Valente ,  Carol Hui Hu ,  Oz Scott Halpern ,  Sutjano Jusuf

IPC: C07D519/00 ,  A61P9/10

Abstract: The present invention provides compounds of Formula (I): wherein the substituents are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, and may be useful for for the treatment and/or prophylaxis of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.